In a retrospective study on BM-MSC therapy for GVHD, MSC-treated patients had lower proportions of HLA-DR+CD4+ cells at day 90 and of HLA-DR+CD8+ cells at day 180 post-MSC infusions (68). This evidence concerns the gene CD8A and graft versus host disease.